Which is the better buy? GlaxoSmithKline plc vs Shire plc

Shire plc (LON: SHP) and GlaxoSmithKline plc (LON: GSK) are two very different companies, but which deserves your cash?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shire (LSE: SHP) and GlaxoSmithKline (LSE: GSK) are two of the UK’s premier pharmaceutical companies but over the past five years, their fortunes couldn’t have been more different.

While Shire’s explosive revenue and income growth has propelled the company’s shares higher, Glaxo has struggled to bring new products to the market and reignite sales growth. Specifically, this year City analysts are expecting a Shire to report revenue of just over $10bn, up a staggering 138% since 2011. Over the same period, the company’s earnings per share are on track to have grown by 158%. For 2017, City analysts have pencilled-in revenue growth of 36% and earnings per share growth of 19.2%.

Glaxo’s earnings per share are expected to grow by 27% this year bringing an end to four years of earnings declines as the company has struggled with falling sales. This year, City analysts are expecting the company to report revenue for the 12-month period of £27bn, which is £400m less than the figure reported for full-year 2011. Over the same period, if the company hits City targets this year, earnings per share will have declined by 19%.

Should you invest £1,000 in Anglo American right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Anglo American made the list?

See the 6 stocks

Buy the underdog? 

After comparing these growth statistics between the two companies, it should come as no surprise that shares in Shire have outperformed those of Glaxo by 135% over the past five years.

Even though I’m usually attracted to the underdog, this time around it looks as if Shire may be the better long-term investment. Granted, Glaxo is returning to growth and the company’s dividend yield, which currently stands at 4.8% is attractive in today’s low-interest rate environment. Nonetheless, when it comes down to valuation, Glaxo looks less attractive than its smaller peer.

Shares in Glaxo currently trade at a forward P/E of 17.3, a valuation that looks rich at first glance but when you consider the company’s defensive nature and attractive dividend yield, it’s understandable. 

However, shares in Shire currently trade at a more attractive forward P/E of 15.6. City analysts are predicting that the company’s earnings per share will grow 79% this year, giving a PEG ratio of 0.2. A PEG ratio of less than one indicates that the shares in question offer growth at a reasonable price. Next year City analysts have pencilled-in earnings per share growth of 19% and on this basis shares in the company are trading at a 2017 P/E of 13.2.

As covered above, Glaxo’s earnings per share are expected to expand by 27% this year, but growth is projected to slow to 7% next year. The shares trade at a PEG ratio of 0.6 for 2016, which clearly shows that they’re less attractive than shares in Shire from a growth perspective.

The bottom line

So overall, while the allure of Glaxo’s market-beating dividend yield may draw investors to the company, Shire looks to be the better pick for growth.

Should you buy Anglo American now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

£10,000 invested in Lloyds shares on 7 April is already worth…

After a dip in early April, Lloyds shares are back to their 30%+ year-to-date gain in 2025. And analysts are…

Read more »

US Stock

What I’d look to buy as the US stock market heads for the worst month since 1932

Jon Smith sifts through the US stock market to try and find some ideas that have fallen in value recently…

Read more »

Growth Shares

Prediction: I think £1,000 invested in this UK stock could double by 2030

Jon Smith runs through a FTSE 250 stock with a market cap just over £1bn that he feels has the…

Read more »

Investing Articles

With £10k in savings, here’s how an investor could target a second income of £500 a month

£10k in savings could be the foundation needed towards a powerful second income. Our writer details some steps necessary to…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing For Beginners

£1k invested in the FTSE 100 on ‘Liberation Day’ is now worth…

Jon Smith talks about the volatility in the FTSE 100 in the weeks since the tariff announcements and flags up…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

Barclays’ share price is down 7% from March, so is now the right time for me to buy?

Barclays’ share price has dipped recently, which could mean a bargain to be had. I took a deep dive into…

Read more »

Investing Articles

Down 13% since March, does this rising FTSE 250 defence star look an unmissable buy for me?

The FTSE 250 is currently home to many of the big stock stars of tomorrow and I think this high-tech…

Read more »

Investing Articles

Should I buy Aston Martin shares for my ISA while they’re under 70p?

With Aston Martin's shares down hugely across multiple time frames, this writer is wondering if he should snap up some…

Read more »